Is Cytomegalovirus Linked to Childhood Leukemia Risk?

Article

Prenatal infection with cytomegalovirus increases the risk of childhood acute lymphoblastic leukemia, indicates a study of newborn blood and pretreatment childhood bone marrow published in the journal Blood.

Prenatal infection with cytomegalovirus (CMV) increases the risk of childhood acute lymphoblastic leukemia (ALL), indicates a study of newborn blood and pretreatment childhood bone marrow published in the journal Blood.

The finding suggests the possibility that ALL could be prevented with antiviral interventions or vaccination.

“If it’s truly that in utero CMV is one of the initiating events in the development of childhood leukemia, then control of the virus has the potential to be a prevention target,” said lead study author Stephen Francis, PhD, assistant professor of epidemiology at the University of Nevada and University of California San Francisco.

Using archived pretreatment bone marrow samples from the California Childhood Leukemia Study at UC Berkeley, the researchers conducted a comprehensive untargeted search for bacteria and all known viruses in marrow from 38 children with acute myeloid leukemia (AML) and 127 children diagnosed with ALL.

Marrow from all of the children with ALL harbored CMV DNA, they discovered. Active CMV transcription was demonstrated in leukemia blasts and intact CMV virions were found in serum.

The research team subsequently screened newborn blood-spot samples for CMV among 268 children who were later diagnosed with ALL and 270 healthy control children. Children who developed ALL were more than three times as likely to have been CMV-positive at birth (odds ratio [OR] 3.71, 95% CI: 1.56-792; P = .0016).

The association between in-utero CMV infection and subsequent development of ALL was particularly strong among Hispanic children (OR 5.90; 95% CI: 1.89-25.96; P = .006).

“This is the first step, but if we do end up finding a causal link to the most common childhood cancer, we hope that will light a fire in terms of stopping mother-to-child transmission of CMV,” said Francis.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Related Content